Pharmaceuticals News and Research

RSS

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

WHO delivers over 125 tons of medical equipment, medicines to health providers in Aleppo

Over the past 2 weeks WHO delivered 2 shipments with more than 125 tons of medical equipment and medicines to health providers in Aleppo, Syrian Arab Republic - in both government-controlled and in opposition-controlled areas. All shipments contained surgical materials, medicines to treat chronic and infectious diseases, infant incubators, ventilators and intensive care unit beds.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

10 simple points to know and monitor alcohol intake

Much the same way individuals are encouraged to know their blood pressure and cholesterol numbers to maintain a healthy lifestyle, a new editorial in the Journal of Psychopharmacology urges the European public to know and monitor their alcohol intake number using a simple 10 point plan.

7 Jan 2014

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration has accepted and filed for review the company's Biologics License Application for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism.

7 Jan 2014

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

7 Jan 2014

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.

7 Jan 2014

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Fungi have played a large role in the development of many important drugs that are in wide use today. The most well-known of these are the penicillins.

7 Jan 2014

Knipper acquires MediMedia Health's sample management lines of business

J. Knipper and Company, Inc., the largest supplier of end-to-end samples management services to the U.S. pharmaceutical industry, announced today that the Company has acquired MediMedia Health's sample management lines of business. These services include direct-to- provider sample fulfillment, patient assistance programs and animal health services, as well as call center and regulatory compliance services that accompany these activities. Terms of the agreement were not disclosed.

7 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

CMS report shows slower growth in health spending with the Affordable Care Act implementation

Today, the Centers for Medicare and Medicaid Services issued findings that show slower growth in health spending since the implementation of the Affordable Care Act. This successful cost control is consistent with data demonstrating that savings from generic medicines are at an all-time high, reaching $217 billion in 2012 and $1.2 trillion over the most recent decade, according to the 2013 Report on Generic Drug Savings in the U.S., the fifth annual report compiled by IMS Health on behalf of the Generic Pharmaceutical Association.

7 Jan 2014

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

7 Jan 2014

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.

6 Jan 2014

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.

6 Jan 2014

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

6 Jan 2014

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Aratana Therapeutics, Inc., a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.

6 Jan 2014

Pharmaceuticals News and Research

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

WHO delivers over 125 tons of medical equipment, medicines to health providers in Aleppo

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

10 simple points to know and monitor alcohol intake

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Knipper acquires MediMedia Health's sample management lines of business

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

CMS report shows slower growth in health spending with the Affordable Care Act implementation

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Portage acquires approximately 54% equity in Biohaven

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Aratana Therapeutics announces acquisition of Okapi Sciences NV

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence